Sign In
Search Icon
Menu Icon

COVID-19 Therapeutics: Resources for Health Care Professionals and Public Health Officials

COVID-19 therapeutics can be used to prevent or treat eligible non-hospitalized patients who have mild to moderate COVID-19 symptoms. Prevention and early treatment for eligible patients can help improve patient outcomes, reduce stress on health care facilities, and even save lives. For details on patient eligibility, see the Side-by-Side Overview of Therapeutics Authorized or Approved for the Treatment of Mild to Moderate COVID-19.

HHS/ASPR purchased supplies of COVID-19 therapeutic products for outpatient use. Now that these products have transitioned to commercial market, HHS continues to work with state and territorial health departments as well as national health care and medical organizations and associations to maximize access to COVID-19 treatments.

On November 1, 2023, Lagevrio and Paxlovid became commercially available, and patient assistance programs are now available for eligible individuals. To learn more about these programs and about HHS distribution timelines of HHS-procured inventory, please see Sunsetting the U.S. Government COVID-19 Therapeutics Distribution Program.

Featured Resources

Outpatient COVID-19 Therapeutics

Oral Antiviral. Paxlovid (nirmatrelvir co-packaged with ritonavir). Federally Distributed. Learn More.  
Oral Antiviral. Lagevrio (molnupiravir). Federally Distributed. Learn More. 
IV Antiviral. Veklury (remdesivir). Commercially Available. Learn More. 

Pre-exposure prophylaxis

People who are moderately or severely immunocompromised, are aged 12 and older, and who weigh at least 88 pounds may be eligible to get Pemgarda (pemivibart), a monoclonal antibody authorized to help protect against COVID-19. Pemgarda is not a treatment for COVID-19.

Previously Available COVID-19 Therapeutic Products

The products listed below are not currently authorized in the U.S because they are not expected to be effective against the currently circulating SARS-CoV-2 variants. Providers with non-expired inventory of these products are encouraged to retain them, as they have the potential to treat future variants more effectively.

Increasing Access to COVID-19 Therapeutics